Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidema and coronary artery disease

American Journal of Cardiology

Volumn 80, Issue 2, 1997, Pages 111-115

  Brown, B Greg ^a,b   Bardsley, Joanna ^a   Poulin, Drew ^a   Hillger, Lynn A ^a   Dowdy, Alice ^a   Maher, Vincent M G ^a   Zhao, Xue Qiao ^a   Albers, John J ^a   Knopp, Robert H ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTIPOL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY DISEASE; DOSE RESPONSE; EDUCATION PROGRAM; GASTROINTESTINAL SYMPTOM; HEMORRHOID; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERLIPIDEMIA; MALE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 0030746239     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00303-2     Document Type: Article

References (28)

1. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
2. Brown BG, Sacco D, Zhao X-Q, Albers JJ. Lipid-lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781-1791.
3. Brown BG, Albers JJ, Fisher LD, Schaeffer SM, Lin J-T, Kaplan C, Zhao X-Q, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-1298.
4. Ad Hoc Committee to Design a Dietary Treatment of Hyperlipoproteinemia. Recommendations for treatment of hyperlipidemia in adults: a joint statement of the Nutrition Committee and the Council on Arteriosclerosis. Circulation 1984;69(5):1065A-1090A.
5. Warnick GR. Enzymatic methods for quantification of lipoprotein lipids. In: Albers JJ, Segrest JP (eds). Plasma Lipoproteins: Part B, Characterization, Cell Biology, and Metabolism. Methods in Enzymology. Vol. 129. Orlando, FL: Academic Press, 1986:101-123.
6. Bachorik PS, Albers JJ. Precipitation methods for quantification of lipoproteins. In: Albers JJ, Segrest JP (eds). Plasma Lipoproteins: Part B, Characterization, Cell Biology, and Metabolism. Methods in Enzymology. Vol. 129. Orlando, FL: Academic Press, 1986:78-100.
7. Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry Standardization Project for measurements of apolipoproteins A-1 and B. III. Comparability of apolipoprotein A-1 values by use of international reference material. Clin Chem 1993;39:773-781.
8. Gass JD. Nicotinic acid maculopathy. Am J Opthalmol 1973;76:500-510.
9. Knopp RH, Ginsberg J, Albers JJ, Hoff C, Ogilvie JT, Warnick GR, Burrows E, Retzlaff B, Poole M. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985;34:642-650.
10. Keenan JM, Ripsin CM, Huang Z-Q, McCaffrey DJ. Safety and side effects of sustained-release niacin (lett). JAMA 1994;272:513.
11. Rivin AU. Jaundice occurring during nicotinic acid therapy for hypercholesterolemia. JAMA 1959;170:2088-2089.
12. Clementz GL, Holmes AW. Nicotinic acid-induced fulminant hepatic failure. J Clin Gastroentero 1987;9:582-584.
13. Alderman JD, Pasternak RC, Sacks FM, Smith HS, Monrad ES, Grossman W. Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. Am J Cardiol 1989;64:725-729.
14. Fischer DJ, Knight LL, Vestal RE. Fulminant hepatic failure following low-dose sustained-release niacin therapy in hospital. West J Med 1991;155:410-412.
15. Mullin GE, Greenson JK, Mitchell MC. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann Intern Med 1989;111:253-255.
16. Rader J. Hepatotoxicity of unmodified and time-release niacin. Am J Med 1992;92:777ndash;781.
17. Etchason JA, Miller TD, Squires RW, Allison TG, Gau GT, Marttila JK, Kottke BA. Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. Mayo Clinic Proc 1991;66:23-28.
18. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-677.
19. Keenan JM, Fontaine PL, Went JB, Myers S, Huang ZQ, Ripsin CM. Niacin revisited: a randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med 1991;151:1424-1432.
20. Gray DR, Morgan T, Chretien SD, Kashyap ML. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Int Med 1994;121:252-258.
21. Kane JP, Malloy MJ. Treatment of hypercholesterolemia. Med Clin North Amer 1982;66:542-543.
22. Litin SC, Anderson CF. Nicotinic acid myopathy: a report of three cases. Am J Med 1989;86:481-483.
23. Gharavi AG, Diamond JA, Smith DA, Phillips RA. Niacin-induced myopathy. Am J Cardiol 1994;74:841-842.
24. Cooke HM. Lovastatin- and niacin-induced rhabdomyolysis. Hosp Pharm 1994;29:33-34.
25. Norman DJ, Illingsworth DR, Munson J, Hsenpud J. Myolysis and acute renal failure in a heart transplant recipient receiving lovastatin (and niacin and cyclosporine) (lett). N Engl J Med 1988;318:40-47.
26. Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis (lett). Ann Int Med 1988;109:597-598.
27. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J, Hurley DP, Longendorfer A, Nash DT, Pool JL, Schnaper H. Expanded clinical evaluation of lovastatin (EXCEL) study results. I efficiency in modifying plasma lipoproteins and adverse event profile in 8,245 patients with moderate hypercholesterolemia. Arch Int Med 1991; 151:43-49.
28. Tobert JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation (letter). N Engl J Med 1988; 318:48.